EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI –
Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for
orthopedics, today announced the launch of EOSone, its new Private
Practice Program, at Becker’s 16th Annual Future of Spine +
The Spine, Orthopedic and Pain Management-Driven ASC Conference, being
held June 14-16 in Chicago.
The EOSone program is designed to address the unique needs of private
practices and to ensure that safe imaging is available to all patients,
not just those treated in a traditional hospital environment. The
program includes support to assist sites with patient communication and
education about low dose, 3D imaging, and patient specific surgical
planning with respect to their conditions and treatment plans.
“In the U.S., the private practice sector accounts for 73 percent of
all orthopedic practices*, representing a significant opportunity for
the EOS technology,” said Marie Meynadier, Chief Executive Officer
of EOS imaging. “We launched the EOSone program as an option for
private clinics to better inform patients interested in safe and
personalized orthopedic care about our EOS platform, 3D models, and
surgical planning solutions. We also include in this program customized
financing options to facilitate access for private practices to our
Because private practices are often hindered by the initial/upfront
investment associated with capital equipment, the EOSone program offers
sites various options to match the sites’ estimated volumes, with access
to the full suite of EOS products, including 3D services, 3D surgical
planning solutions, and system services, training, support, and updates
for the duration of the program.
Spine: 11 Statistics and Facts About Orthopedics and
About EOS imagingEOS imaging designs, develops and markets
EOS®, a major innovative medical imaging solution dedicated to
osteoarticular pathologies and orthopedics combining equipment and
services and targeting a $2B per year market opportunity. EOS imaging is
currently present in 31 countries, including the United States under FDA
agreement, Japan, China and the European Union under CE labelling,
through the over 250 installed EOS® platforms representing around one
million patient exams every year. Revenues were €37.1M in 2017, e.g. a
+32% CAGR over 2012-2017.
For more information, please visit www.eos-imaging.com.
EOS imaging has been selected to integrate the EnterNext © PEA – PME
150 index, composed of 150 French, listed companies on the Euronext
markets in Paris.
EOS imaging is listed on Compartment C of Euronext ParisISIN:
FR0011191766 – Ticker: EOSI
View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005447/en/